317 related articles for article (PubMed ID: 23204401)
1. Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis.
Lesher AM; Zhou L; Kimura Y; Sato S; Gullipalli D; Herbert AP; Barlow PN; Eberhardt HU; Skerka C; Zipfel PF; Hamano T; Miwa T; Tung KS; Song WC
J Am Soc Nephrol; 2013 Jan; 24(1):53-65. PubMed ID: 23204401
[TBL] [Abstract][Full Text] [Related]
2. Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency.
Ruseva MM; Vernon KA; Lesher AM; Schwaeble WJ; Ali YM; Botto M; Cook T; Song W; Stover CM; Pickering MC
J Am Soc Nephrol; 2013 Jan; 24(1):43-52. PubMed ID: 23184055
[TBL] [Abstract][Full Text] [Related]
3. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.
Williams AL; Gullipalli D; Ueda Y; Sato S; Zhou L; Miwa T; Tung KS; Song WC
Kidney Int; 2017 Jun; 91(6):1386-1397. PubMed ID: 28139294
[TBL] [Abstract][Full Text] [Related]
4. Unexpected role for properdin in complement C3 glomerulopathies.
Daha MR
J Am Soc Nephrol; 2013 Jan; 24(1):5-7. PubMed ID: 23243211
[No Abstract] [Full Text] [Related]
5. Dense deposit disease and C3 glomerulopathy.
Barbour TD; Pickering MC; Terence Cook H
Semin Nephrol; 2013 Nov; 33(6):493-507. PubMed ID: 24161036
[TBL] [Abstract][Full Text] [Related]
6. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
[TBL] [Abstract][Full Text] [Related]
7. Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia.
Ueda Y; Miwa T; Gullipalli D; Sato S; Ito D; Kim H; Palmer M; Song WC
J Am Soc Nephrol; 2018 Jul; 29(7):1928-1937. PubMed ID: 29858280
[No Abstract] [Full Text] [Related]
8. Liver factor B silencing to cure C3 glomerulopathy: Evidence from a mouse model of complement dysregulation.
Zanchi C; Locatelli M; Corna D; Cerullo D; Fishilevich E; Desai D; Rottoli D; Donadelli R; Noris M; Zoja C; Remuzzi G; Benigni A
Mol Immunol; 2023 Sep; 161():25-32. PubMed ID: 37481826
[TBL] [Abstract][Full Text] [Related]
9. C3 dysregulation due to factor H deficiency is mannan-binding lectin-associated serine proteases (MASP)-1 and MASP-3 independent in vivo.
Ruseva MM; Takahashi M; Fujita T; Pickering MC
Clin Exp Immunol; 2014 Apr; 176(1):84-92. PubMed ID: 24279761
[TBL] [Abstract][Full Text] [Related]
10. Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy.
Vernon KA; Ruseva MM; Cook HT; Botto M; Malik TH; Pickering MC
J Am Soc Nephrol; 2016 May; 27(5):1334-42. PubMed ID: 26374608
[TBL] [Abstract][Full Text] [Related]
11. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN.
Wong EK; Anderson HE; Herbert AP; Challis RC; Brown P; Reis GS; Tellez JO; Strain L; Fluck N; Humphrey A; Macleod A; Richards A; Ahlert D; Santibanez-Koref M; Barlow PN; Marchbank KJ; Harris CL; Goodship TH; Kavanagh D
J Am Soc Nephrol; 2014 Nov; 25(11):2425-33. PubMed ID: 24722444
[TBL] [Abstract][Full Text] [Related]
13. An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.
Yang Y; Denton H; Davies OR; Smith-Jackson K; Kerr H; Herbert AP; Barlow PN; Pickering MC; Marchbank KJ
J Am Soc Nephrol; 2018 Jun; 29(6):1649-1661. PubMed ID: 29588430
[No Abstract] [Full Text] [Related]
14. Retinal Basal Laminar Deposits in Complement fH/fP Mouse Model of Dense Deposit Disease.
Song D; Mohammed I; Bhuyan R; Miwa T; Williams AL; Gullipalli D; Sato S; Song Y; Dunaief JL; Song WC
Invest Ophthalmol Vis Sci; 2018 Jul; 59(8):3405-3415. PubMed ID: 30025090
[TBL] [Abstract][Full Text] [Related]
15. von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study.
Chen YY; Han SS; Cao Y; Yu XJ; Zhu L; Luo JC; Song WC; Yu F; Mao YH; Zhao MH
Clin Immunol; 2021 Aug; 229():108794. PubMed ID: 34245915
[TBL] [Abstract][Full Text] [Related]
16. Complement activity is regulated in C3 glomerulopathy by IgG-factor H fusion proteins with and without properdin targeting domains.
Gilmore AC; Zhang Y; Cook HT; Lavin DP; Katti S; Wang Y; Johnson KK; Kim S; Pickering MC
Kidney Int; 2021 Feb; 99(2):396-404. PubMed ID: 33129896
[TBL] [Abstract][Full Text] [Related]
17. Humanized C3 Mouse: A Novel Accelerated Model of C3 Glomerulopathy.
Devalaraja-Narashimha K; Meagher K; Luo Y; Huang C; Kaplan T; Muthuswamy A; Halasz G; Casanova S; O'Brien J; Peyser Boiarsky R; McWhirter J; Gartner H; Bai Y; MacDonnell S; Liu C; Hu Y; Latuszek A; Wei Y; Prasad S; Huang T; Yancopoulos G; Murphy A; Olson W; Zambrowicz B; Macdonald L; Morton LG
J Am Soc Nephrol; 2021 Jan; 32(1):99-114. PubMed ID: 33288630
[TBL] [Abstract][Full Text] [Related]
18. C3 glomerulopathy: what's in a name?
D'Agati VD; Bomback AS
Kidney Int; 2012 Aug; 82(4):379-81. PubMed ID: 22846813
[TBL] [Abstract][Full Text] [Related]
19. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy.
Hawfield A; Iskandar SS; Smith RJ
Am J Kidney Dis; 2013 May; 61(5):828-31. PubMed ID: 23391537
[TBL] [Abstract][Full Text] [Related]
20. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis.
Licht C; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):271-8. PubMed ID: 19190809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
